[Adjuvant therapy with systemic JM-8 (carboplatin) in superficial bladder tumors. Results after 3 years of use]

We evaluated the 3-year efficacy of adjuvant treatment (after complete TUR) with systemic carboplatin in 34 patients with transitional cell bladder tumors in the superficial stages. Twenty-six patients with a one-year follow-up had a recurrence rate of 23%. Twenty-three patients with a two-year follow-up had a recurrence rate of 65.3%. Six patients with a three-year follow-up had a recurrence rate of 83.3%. Seventeen patients with tumor recurrence within three years had "minimal" recurrence. The course of the disease was very stable and remained unchanged in 4 cases that required no other treatment for one year. This treatment modality indicates a therapeutic effect; however, further studies and changes are warranted in order to obtain better results.